Smart insulin pump aims to end dangerous nighttime blood sugar swings

NCT ID NCT02438189

Completed Disease control Sponsor: Jaeb Center for Health Research Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests a smart insulin pump algorithm designed to automatically adjust insulin delivery during the night to keep blood sugar levels in a safe range. The algorithm predicts when blood sugar might drop too low and pauses insulin, and when it might rise too high, it gives extra insulin. The study involves about 30 people with type 1 diabetes who use an insulin pump, and it compares nights with the algorithm on versus off to see if it improves time in the target range and reduces dangerous highs and lows.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A smart insulin pump algorithm that automatically adjusts insulin delivery overnight to prevent blood sugar from going too high or too low.
What this could lead to: If successful, this could lead to a more automated insulin pump system that helps people with type 1 diabetes maintain safer blood sugar levels overnight, reducing the risk of dangerous nighttime episodes.
What could go wrong: This is a small, early feasibility study, so results may not apply to everyone. The algorithm may not always predict correctly, and there is a risk of severe hypoglycemia or diabetic ketoacidosis, though the trial monitors for these.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperglycemia hypoglycemia type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Barbara Davis Center for Childhood Diabetes

Aurora, Colorado, 80045, United States
St. Joseph's Health Care

London, Ontario, N6A4V2, Canada
Stanford University

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.